This trial is testing a new imaging agent, [18F]FluorThanatrace, to see if it can improve imaging techniques in patients with breast cancer.
1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year
Experimental Treatment
36 Total Participants · 1 Treatment Group
Primary Treatment: Fluorine F 18 Fluorthanatrace · No Placebo Group · Phase 2
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: